Product Description: Desloratadine (Sch34117) is an orally active and selective H1 receptor antagonist (Ki=0.9 nM) with anti-inflammatory and anti-allergic activities. Desloratadine inhibits the release of histamine and LTC4 from human basophils and targets the regulatory signals of IL-4 and IL-13 production in basophils. Desloratadine significantly alleviates SAR symptoms in patients with concurrent asthma and can be used in the study of seasonal allergic rhinitis and chronic idiopathic urticaria[1][2][3][4][5][6].
Applications: COVID-19-immunoregulation
Formula: C19H19ClN2
References: [1]Geha, R.S. and E.O. Meltzer, Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol, 2001. 107(4): p. 751-62./[2]Schroeder, J.T., et al., Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy, 2001. 31(9): p. 1369-77./[3]Anthes, J.C., et al., Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol, 2002. 449(3): p. 229-37./[4]McClellan K, et al. Desloratadine. Drugs. 2001;61(6):789-797./[5]Agrawal, et al. "Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug." Expert opinion on investigational drugs 10.3 (2001): 547-560./[6]Kowalski, et al. "Inhibition of nasal polyp mast cell and eosinophil activation by desloratadine." Allergy 60.1 (2005): 80-85.
CAS Number: 100643-71-8
Molecular Weight: 310.82
Compound Purity: 99.98
Research Area: Inflammation/Immunology
Solubility: DMSO : 25 mg/mL (ultrasonic)/H2O : < 0.1 mg/mL
Target: Endogenous Metabolite;Histamine Receptor;Leukotriene Receptor;Platelet-activating Factor Receptor (PAFR) ;TNF Receptor
English
Deutsch
